Corcept Therapeutics Incorporat
Corcept Therapeutics develops treatments for severe disorders. They offer Korlym tablets for endogenous Cushings syndrome. Relacorilant is in Phase III trials for Cushings syndrome, adrenal cancer, cortisol excess, prostate cancer, and platinum-resistant ovarian tumors. Dazucorilant is in Phase II trial for amyotrophic lateral sclerosis. Miricorilant is in Phase IIb trial for nonalcoholic steatohepatitis. They also develop treatments for antipsychotic-induced weight gain.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and an asset-light, cash-generative model.
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 21.7%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 21.7% against a cost of capital (WACC) of 6.4%, a spread of 15.3 percentage points.
- Asset-light, cash-generative model: capital expenditure takes only 0.2% of revenue and free cash flow was positive in each of the last 6 years.
- Consistent growth: revenue has compounded at 16.6% a year over 5 years, rising every year.
- Net cash balance sheet: cash exceeds total debt.
Weaknesses
- Our discounted cash flow target price (10.77 USD) is 85% below the current price.
- Valued at a premium to its Biotechnology peers: P/E 76.2x vs. a median of 19.2x and P/FCF 53.5x vs. a median of 18.8x.
- More expensive than its own history: P/E 76.2x vs. a historical average of 32.2x and P/FCF 53.5x vs. a historical average of 23.8x.
Key Financial Data